Addressing hyperglycemia from hospital admission to discharge

Current Medical Research and Opinion

Volumn 26, Issue 3, 2010, Pages 589-598

  Moghissi, Etie S ^a  

^a University of California   (United States)

Author keywords

Diabetes; Hospital; Hyperglycemia; Hypoglycemia; Insulin; Insulin analog

Indexed keywords

GLUCOSE; INSULIN; INSULIN ASPART; INSULIN DERIVATIVE; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; ISOPHANE INSULIN; RECOMBINANT HUMAN INSULIN;

BLOOD GLUCOSE MONITORING; BOLUS INJECTION; CONTINUOUS INFUSION; CRITICALLY ILL PATIENT; DIABETES MELLITUS; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HOSPITAL ADMISSION; HOSPITAL CARE; HOSPITAL DISCHARGE; HOSPITAL PATIENT; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN TREATMENT; REVIEW;

HOSPITALIZATION; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; MONITORING, PHYSIOLOGIC; PATIENT DISCHARGE;

EID: 76949097240     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990903566822     Document Type: Review

References (94)

1. American Diabetes Association. Economic costs of diabetes in the U.S. in 2007. Diabetes Care 2008;31:596-615
2. Clement S, Braithwaite SS, Magee MF, et al. Management of diabetes and hyperglycemia in hospitals. Diabetes Care 2004;27:553-591
3. Umpierrez GE, Isaacs SD, Bazargan N, et al. Hyperglycemia: an independent marker of in-hospital mortality in patients with undiagnosed diabetes. J Clin Endocrinol Metab 2002;87:978-982
4. Campbell RK. Etiology and effect on outcomes of hyperglycemia in hospitalized patients. Am J Health Sys Pharm 2007;64:S4-8
5. Asadollahi K, Beeching N, Gill G. Hyperglycaemia and mortality. J R Soc Med 2007;100:503-507
6. Sheetz MJ, King GL. Molecular understanding of hyperglycemia's adverse effects for diabetic complications. JAMA 2002;288:2579-2588
7. Williams LS, Rotich J, Qi R, et al. Effects of admission hyperglycemia on mortality and costs in acute ischemic stroke. Neurology 2002;59:67-71
8. Krinsley JS. Association between hyperglycemia and increased hospital mortality in a heterogeneous population of critically ill patients. Mayo Clin Proc 2003;78:1471-1478
9. Estrada CA, Young JA, Nifong LW, et al. Outcomes and perioperative hyper-glycemia in patients with or without diabetes mellitus undergoing coronary artery bypass grafting. Ann Thorac Surg 2003;75:1392-1399
10. Pomposelli JJ, Baxter III JK, Babineau TJ, et al. Early postoperative glucose control predicts nosocomial infection rate in diabetic patients. JPEN J Parenter Enteral Nutr 1998;22:77-81
11. Capes SE, Hunt D, Malmberg K, et al. Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview. Lancet 2000;355:773-778
12. Moghissi ES, Kongable GL, Abad VJ, et al. Current state of inpatient diabetes burden and care, and goal of the conference. Endocr Pract 2006;12:1-10
13. Olson L, Muchmore J, Lawrence CB. The benefits of inpatient diabetes care: improving quality of care and the bottom line. Endocr Pract 2006;12 (Suppl 3):35-42
14. Newton CA, Young S. Financial implications of glycemic control: results of an inpatient diabetes management program. Endocr Pract 2006;12(Suppl 3): 43-48
15. Van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in critically ill patients. N Engl J Med 2001;345:1359-1367
16. Garber AJ, Moghissi ES, Bransome Jr ED, et al. American College of Endocrinology position statement on inpatient diabetes and metabolic control. Endocr Pract 2004;10:77-82
17. ACE/ADA Task Force on Inpatient Diabetes. American College of Endocrinology and American Diabetes Association consensus statement on inpatient diabetes and glycemic control. Endocr Pract 2006;12:458-468
18. American Diabetes Association. Standards of medical care in diabetes-2009. Diabetes Care 2009;32(Suppl 1):S13-61
19. Moghissi ES, Korytkowski MT, Dinardo M, et al. American Association of Clinical Endocrinologists and American Diabetes Association Consensus Statement on Inpatient Glycemic Control. Endocr Pract 2009; 15:1-17
20. Van den Berghe G, Wilmer A, Hermans G, et al. Intensive insulin therapy in the medical ICU. N Engl J Med 2006;354:449-461
21. Krinsley JS. Effect of an intensive glucose management protocol on the mortality of critically ill adult patients. Mayo Clin Proc 2004;79:992-1000
22. Wiener RS, Wiener DC, Larson RJ. Benefits and risks of tight glucose control in critically ill adults: a meta-analysis. JAMA 2008;300:933-944
23. Finfer S, Chittock DR, Su SY, et al. Intensive versus conventional glucose control in critically ill patients. N Engl J Med 2009;360:1283-1297
24. Griesdale DE, de Souza RJ, van Dam RM, et al. Intensive insulin therapy and mortality among critically ill patients: a meta-analysis including NICE-SUGAR study data. CMAJ 2009;180:821-827
25. Brunkhorst FM, Engel C, Bloos F, et al. Intensive insulin therapy and pentas-tarch resuscitation in severe sepsis. N Engl J Med 2008;358:125-139
26. De La Rosa GC, Donado JH, Restrepo AH, et al. Strict glycaemic control in patients hospitalised in a mixed medical and surgical intensive care unit: a randomised clinical trial. Crit Care 2008;12:R120
27. Ahmann AJ. Inpatient management of hospitalized patients with type 2 diabetes. Curr Diab Rep 2004;4:346-351
28. Ku SY, Sayre CA, Hirsch IB, et al. New insulin infusion protocol improves blood glucose control in hospitalized patients without increasing hypoglycemia. Jt Comm J Qual Patient Saf 2005;31:141-147
29. Goldberg PA, Siegel MD, Sherwin RS, et al. Implementation of a safe and effective insulin infusion protocol in a medical intensive care unit. Diabetes Care 2004;27:461-467
30. Markovitz LJ, Wiechmann RJ, Harris N, et al. Description and evaluation of a glycemic management protocol for patients with diabetes undergoing heart surgery. Endocr Pract 2002;8:10-18
31. Portland Diabetic Project. Portland protocol 2008. Available at: http://www.providence.org/oregon/programs-and-services/heart/portlandprotocol
32. Furnary AP, Cheek DB, Holmes SC, et al. Achieving tight glycemic control in the operating room: lessons learned from 12 years in the trenches of a paradigm shift in anesthetic care. Semin Thorac Cardiovasc Surg 2006; 18:339-345
33. Maynard G, O'Malley CW, Kirsh SR. Perioperative care of the geriatric patient with diabetes or hyperglycemia. Clin Geriatr Med 2008;24:649-665
34. Capes SE, Hunt D, Malmberg K, et al. Stress hyperglycemia and prognosis of stroke in nondiabetic and diabetic patients: a systematic overview. Stroke 2001;32:2426-2432
35. Zarich SW. Mechanism by which hyperglycemia plays a role in the setting of acute cardiovascular illness. Rev Cardiovasc Med 2006;7(Suppl 2):S35-43
36. McAlister FA, Majumdar SR, Blitz S, et al. The relation between hyperglycemia and outcomes in 2,471 patients admitted to the hospital with community-acquired pneumonia. Diabetes Care 2005;28:810-815
37. Furnary AP, Zerr KJ, Grunkemeier GL, et al. Continuous intravenous insulin infusion reduces the incidence of deep sternal wound infection in diabetic patients after cardiac surgical procedures. Ann Thorac Surg 1999; 67:352-360
38. Furnary AP, Wu Y. Clinical effects of hyperglycemia in the cardiac surgery population: the Portland Diabetic Project. Endocr Pract 2006;12(Suppl 3):22-26
39. Meneghini LF. Perioperative management of diabetes: translating evidence into practice. Cleve Clin J Med 2009;76(Suppl 4):S53-9
40. Maynard G, Lee J, Phillips G, et al. Improved inpatient use of basal insulin, reduced hypoglycemia, and improved glycemic control: effect of structured subcutaneous insulin orders and an insulin management algorithm. J Hosp Med 2009;4:3-15
41. Furnary AP, Braithwaite SS. Effects of outcome on in-hospital transition from intravenous insulin infusion to subcutaneous therapy. Am J Cardiol 2006;98:557-564
42. Magee MF. Hospital protocols for targeted glycemic control: development, implementation, and models for cost justification. Am J Health Sys Pharm 2007;64:S15-20
43. Donaldson S, Villanuueva G, Rondinelli L, et al. Rush University guidelines and protocols for the management of hyperglycemia in hospitalized patients: elimination of the sliding scale and improvement of glycemic control throughout the hospital. Diabetes Educ 2006;32:954-962
44. Magee MF, Clement S. Subcutaneous insulin therapy in the hospital setting: issues, concerns, and implementation. Endocr Pract 2004;10(Suppl 2):81-88
45. Moghissi E. Hospital management of diabetes: beyond the sliding scale. Cleve Clin J Med 2004;71:801-808
46. Moghissi ES, Hirsch IB. Hospital management of diabetes. Endocrinol Metab Clin North Am 2005;34:99-116
47. Trence DL, Kelly JL, Hirsch IB. The rationale and management of hypergly-cemia for in-patients with cardiovascular disease: time for change. J Clin Endocrinol Metab 2003;88:2430-2437
48. Cook CB, Stockton L, Baird M, et al. Working to improve care of hospital hyperglycemia through statewide collaboration: the Georgia Hospital Association Diabetes Special Interest Group. Endocr Pract 2007;13:45-50
49. Reynolds LR, Cook AM, Lewis DA, et al. An institutional process to improve inpatient glycemic control. Qual Manag Health Care 2007;16:239-249
50. Cohen LS, Sedhom L, Salifu M, et al. Inpatient diabetes management: examining morning practice in an acute care setting. Diabetes Educ 2007; 33:483-492
51. Lubitz CC, Seley JJ, Rivera C, et al. The perils of inpatient hyperglycemia management: how we turned apathy into action. Diabetes Spectr 2007; 20:18-21
52. DeSantis AJ, Schmeltz LR, Schmidt K, et al. Inpatient management of hyperglycemia: the Northwestern experience. Endocr Pract 2006;12:491-505
53. Baldwin D, Villanueva G, McNutt R, et al. Eliminating inpatient sliding-scale insulin: a reeducation project with medical house staff. Diabetes Care 2005; 28:1008-1011 (Pubitemid 40616604)
54. Huffman M. Health coaching: a new and exciting technique to enhance patient self-management and improve outcomes. Home Healthc Nurse 2007; 25:271-274
55. Mullen BA, Kelley PA. Diabetes nurse case management: an effective tool. J Am Acad Nurse Pract 2006;18:22-30
56. Hirsch IB. Sliding scale insulin-time to stop sliding. JAMA 2009;301:213-214
57. Queale WS, Seidler AJ, Brancati FL. Glycemic control and sliding scale insulin use in medical inpatients with diabetes mellitus. Arch Intern Med 1997; 157:545-552
58. Golightly LK, Jones MA, Hamamura DH, et al. Management of diabetes mellitus in hospitalized patients: efficiency and effectiveness of sliding-scale insulin therapy. Pharmacotherapy 2006;26:1421-1432
59. Wexler DJ, Meigs JB, Cagliero E, et al. Prevalence of hyper-and hypoglyce-mia among inpatients with diabetes: a national survey of 44 U.S. hospitals. Diabetes Care 2007;30:367-369
60. Becker T, Moldoveanu A, Cukierman T, et al. Clinical outcomes associated with the use of subcutaneous insulin-by-glucose sliding scales to manage hyperglycemia in hospitalized patients with pneumonia. Diabetes Res Clin Pract 2007;78:392-397
61. Umpierrez GE, Smiley D, Zisman A, et al. Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes (RABBIT 2 trial). Diabetes Care 2007;30:2181-2186
62. Schnipper JL, Ndumele CD, Liang CL, et al. Effects of a subcutaneous insulin protocol, clinical education, and computerized order set on the quality of inpatient management of hyperglycemia: results of a clinical trial. J Hosp Med 2009;4:16-27
63. Chapman TM, Perry CM. Insulin detemir: a review of its use in the management of type 1 and 2 diabetes mellitus. Drugs 2004;64:2577-2595
64. Morales J. Defining the role of insulin detemir in basal insulin therapy. Drugs 2007;67:2557-2584
65. Dunn CJ, Plosker GL, Keating GM, et al. Insulin glargine: an updated review of its use in the management of diabetes mellitus. Drugs 2003; 63:1743-1778
66. Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 2009;15:540-559
67. Reynolds NA, Wagstaff AJ. Insulin aspart: a review of its use in the management of type 1 or 2 diabetes mellitus. Drugs 2004;64:1957-1974
68. Robinson DM, Wellington K. Insulin glulisine. Drugs 2006;66:861-869
69. Simpson D, McCormack PL, Keating GM, et al. Insulin lispro: a review of its use in the management of diabetes mellitus. Drugs 2007;67:407-434 (Pubitemid 46437098)
70. Brunton SA. Nocturnal hypoglycemia: answering the challenge with long-acting insulin analogs. Med Gen Med 2007;9:38
71. Rossetti P, Porcellati F, Bolli GB, et al. Prevention of hypoglycemia while achieving good glycemic control in type 1 diabetes: the role of insulin analogs. Diabetes Care 2008;31(Suppl 2):S113-20
72. Davis S, Alonso MD. Hypoglycemia as a barrier to glycemic control. J Diabetes Complications 2004;18:60-68
73. Fulcher GR, Gilbert RE, Yue DK. Glargine is superior to neutral protamine Hagedorn for improving glycated haemoglobin and fasting blood glucose levels during intensive insulin therapy. Intern Med J 2005;35:536-542
74. Rosenstock J, Dailey G, Massi-Benedetti M, et al. Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. Diabetes Care 2005;28:950-955
75. Yki-Jarvinen H. The relationship between glycemic control and hypoglycemia using insulin glargine versus NPH insulin: a meta-regression analysis in type 2 diabetes. Diabetes 2003;52(Suppl 1):A149-50
76. Raslova K, Bogoev M, Raz I, et al. Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes. Diabetes Res Clin Pract 2004;66:193-201. [Correction appears in Raslova K, et al. Diabetes Res Clin Pract. 2006;72:112]
77. Haak T, Tiengo A, Draeger E, et al. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabetes Obes Metab 2005; 7:56-64
78. Hermansen K, Davies M, Derezinski T, et al. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care 2006;29:1269-1274
79. Heinemann L. Variability of insulin absorption and insulin action. Diabetes Technol Ther 2002;4:673-682
80. Ratner RE, Hirsch IB, Neifing JL, et al. Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. Diabetes Care 2000;23:639-643
81. Yki-Jarvinen H, Dressler A, Ziemen M, et al. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. Diabetes Care 2000;23:1130-1136
82. Bartley PC, Bogoev M, Larsen J, et al. Long-term efficacy and safety of insulin detemir compared to neutral protamine Hagedorn insulin in patients with type 1 diabetes using a treat-to-target basal-bolus regimen with insulin aspart at meals: a 2-year, randomized, controlled trial. Diabet Med 2008; 25:442-449
83. Heise T, Pieber TR. Towards peakless, reproducible and long-acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studies. Diabetes Obes Metab 2007;9:648-659
84. Home PD, Lindholm A, Hylleberg B, et al. Improved glycemic control with insulin aspart: a multicenter randomized double-blind crossover trial in type 1 diabetic patients. Diabetes Care 1998;21:1904-1909
85. Anderson Jr JH, Brunelle RL, Koivisto VA, et al. Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment. Multicenter Insulin Lispro Study Group. Diabetes 1997;46:265-270
86. Dailey G, Rosenstock J, Moses RG, et al. Insulin glulisine provides improved glycemic control in patients with type 2 diabetes. Diabetes Care 2004; 27:2363-2368 (Pubitemid 39281386)
87. Heller SR, Amiel SA, Mansell P. Effect of the fast-acting insulin analog lispro on the risk of nocturnal hypoglycemia during intensified insulin therapy. U.K. Lispro Study Group. Diabetes Care 1999;22:1607-1611
88. Gale EAM. A randomized, controlled trial comparing insulin lispro with human soluble insulin in patients with type 1 diabetes on intensified insulin therapy. Diabet Med 2000;17:209-214
89. Heller S, Colagiuri S, Vaaler S, et al. Reduced hypoglycemia with insulin aspart: a double-blind, randomized crossover trial in type 1 diabetic patients. Diabetes 2001;50:A137
90. Bottomley JM, Raymond FD. Pharmaco-economic issues for diabetes therapy. Best Pract Res Clin Endocrinol Metab 2007;21:657-685
91. Inzucchi SE. Clinical practice. Management of hyperglycemia in the hospital setting. N Engl J Med 2006;355:1903-1911
92. Fonseca V. Newly diagnosed diabetes/hyperglycemia in hospitals: what should we do? Endocr Pract 2006;12(Suppl 3):108-111
93. Thompson CL, Dunn KC, Menon MC. Hyperglycemia in the hospital. Diabetes Spectr 2005;18:20-27
94. Boyle PJ, Zrebiec J. Management of diabetes-related hypoglycemia. South Med J 2007;100:183-194